(19)
(11)EP 3 626 832 A3

(12)EUROPEAN PATENT APPLICATION

(88)Date of publication A3:
13.05.2020 Bulletin 2020/20

(43)Date of publication A2:
25.03.2020 Bulletin 2020/13

(21)Application number: 19195023.7

(22)Date of filing:  25.11.2015
(51)International Patent Classification (IPC): 
C12Q 1/6883(2018.01)
C12Q 1/6886(2018.01)
(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)Priority: 25.11.2014 US 201462084127 P

(62)Application number of the earlier application in accordance with Art. 76 EPC:
15816941.7 / 3224381

(71)Applicants:
  • The Brigham and Women's Hospital, Inc.
    Boston, MA 02115 (US)
  • The General Hospital Corporation
    Boston, MA 02114 (US)

(72)Inventors:
  • EBERT, Benjamin, Levine
    Brookline, MA 02445 (US)
  • JAISWAL, Siddhartha
    Boston, MA 02115 (US)
  • KATHIRESAN, Sekar
    Cambridge, MA 02145 (US)

(74)Representative: De Clercq & Partners 
Edgard Gevaertdreef 10a
9830 Sint-Martens-Latem
9830 Sint-Martens-Latem (BE)

  


(54)METHOD OF IDENTIFYING AND TREATING A PERSON HAVING A PREDISPOSITION TO OR AFFLICTED WITH A CARDIOMETABOLIC DISEASE


(57) The invention relates to method for identifying and selecting a subject with increased risk of developing a cardiometabolic disease and optionally, providing a personalized medicine method. which may involve sequencing at least part of a genome of one or more cells in a blood sample of the subject and identifying from said sequencing one or more mutations in one or more somatic mutations.





Search report



























Search report